Post Transplant Outcome of a Multicenter Phase II Study of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT
Robert Chen(AstraZeneca (United States)), Stephen J. Forman(City Of Hope National Medical Center), Tanya Siddiqi(City Of Hope National Medical Center), Steven T. Rosen(Unknown), Michelle Mott(City of Hope), Firoozeh Sahebi(City Of Hope National Medical Center), John P. Leonard(New York University), Peter Martin(Northwestern University), Saro H. Armenian(City of Hope), Larry W. Kwak(The University of Texas MD Anderson Cancer Center), Ji‐Lian Cai, Auayporn Nademanee(City Of Hope National Medical Center), Leslie Popplewell(City Of Hope National Medical Center), Ni‐Chun Tsai(City of Hope), Joycelynne Palmer(City of Hope)
Cited by 13
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2016|1.8k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k